Trials / Conditions / BRAF V600 Mutation

BRAF V600 Mutation

21 registered clinical trials studyying BRAF V600 Mutation — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation NCT05275374	Xynomic Pharmaceuticals, Inc.	Phase 1 / Phase 2
Recruiting	Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas NCT07110246	University of California, San Francisco	Phase 2
Enrolling By Invitation	Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance NCT07122882	Chang Gung Memorial Hospital	—
Not Yet Recruiting	Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations NCT06054191	Sun Yat-sen University	Phase 2
Recruiting	Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924	Institut de Recherches Internationales Servier	Phase 1 / Phase 2
Recruiting	Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC NCT05800340	Guangdong Provincial People's Hospital	Phase 2
Active Not Recruiting	Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis NCT04074096	UNICANCER	Phase 2
Terminated	A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors NCT05501912	ABM Therapeutics Shanghai Company Limited	Phase 1
Completed	Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorec NCT05510895	AIO-Studien-gGmbH	Phase 2
Completed	Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations NCT05810740	Pierre Fabre Medicament	Phase 1
Completed	A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) NCT05546905	Pierre Fabre Medicament	—
Unknown	Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations NCT05103891	Pierre Fabre Medicament	Phase 1
Recruiting	Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma NCT04741997	H. Lee Moffitt Cancer Center and Research Institute	EARLY_Phase 1
Completed	BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evalua NCT04775095	Intergroupe Francophone de Cancerologie Thoracique	—
Recruiting	A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) NCT06749015	Fudan University	—
Completed	A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma NCT04911998	Pierre Fabre Medicament	—
Withdrawn	Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma NCT04759846	Pierre Fabre Medicament	Phase 1
Terminated	Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors NCT04190628	ABM Therapeutics Corporation	Phase 1
Completed	Advanced Melanoma in Russian Experience NCT03663647	MelanomaPRO, Russia	—
Terminated	Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases NCT03430947	Technische Universität Dresden	Phase 2
Unknown	To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compare NCT03514901	Intergruppo Melanoma Italiano	Phase 2